INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.

Exclusion criteria

• . Patients eligible for hematopoietic stem cell transplantation (suitable candidate and a suitable donor is available).
• . Patients with history of malignancy in past 3 years except for treated, early-stage squamous or basal cell carcinoma in situ.
• . Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral INC424 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
• . Patients with cardiac disease which in the Investigator's opinion may jeopardize the safety of the patient or the compliance with the protocol.
• . Patients with currently uncontrolled or unstable angina, rapid or paroxysmal atrial fibrillation or recent (approximately 6 months) myocardial infarction or acute coronary syndrome.
• . Patients with clinically significant bacterial, fungal, parasitic or viral infection which require therapy. Patients with acute bacterial infections requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.
• . Patients with known active hepatitis A, B, C or who are HIV-positive.
• . Patients with inadequate bone marrow reserve at the Baseline visit as demonstrated by: